Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | BLM | P54132 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 7/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5248072 | 0.79 | DPP4 (0.36) | — | |
| SCHEMBL20787584 | 0.77 | — | — | |
| SCHEMBL6287397 | 0.77 | TRPA1 (0.30) | — | |
| SCHEMBL6281290 | 0.77 | ALDH1A1 (0.36) | ALDH1A1CYP3A4CYP2D6SLC6A3SLC6A2 | |
| SCHEMBL4094054 | 0.74 | PGR (0.31) | — | |
| SCHEMBL4828130 | 0.74 | PGR (0.31) | — | |
| SCHEMBL19143810 | 0.74 | KDM1A (0.30) | — | |
| SCHEMBL6281286 | 0.74 | AOC3 (0.30) | — | |
| SCHEMBL9823614 | 0.72 | — | — | |
| SCHEMBL9823694 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458719-A1 | PYRIDOQUINOXALINE ANTIVIRALS | PHARMACIA & UPJOHN COMPANY (US) | 2004-09-22 | — | — | EP | claimed |
| US-20030207877-A1 | Pyridoquinoxaline antivirals | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | claimed |
| WO-2003053971-A1 | PYRIDOQUINOXALINE ANTIVIRALS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-03 | — | — | WO | claimed |
| US-20050133763-A1 | Phenylcyclohexanes and a liquid-crystalline medium | WACHTLER ANDREAS (DE) | 2005-06-23 | — | — | US | disclosed |
| US-6878705-B2 | 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamide antiviral agents | PFIZER (US) | 2005-04-12 | — | — | US | disclosed |
| US-20050049245-A1 | Heteroaryl-ethanolamine derivatives as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2005-03-03 | — | — | US | disclosed |
| US-6861438-B2 | Antiviral agents | PFIZER (US) | 2005-03-01 | — | — | US | disclosed |
| US-6852731-B2 | Antiviral compounds | PFIZER (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040259907-A1 | 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY | 2004-12-23 | — | — | US | disclosed |
| WO-2004106345-A2 | HETEROARYL-ETHANOLAMINE DERIVATIVES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY | 2004-12-02 | — | — | US | disclosed |
| EP-1467999-A1 | OXOTHIENO[3,2-B]PYRIDINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1465895-A2 | 4-OXO-4,7-DIHYDROFURO(2,3-B)PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1458719-A1 | PYRIDOQUINOXALINE ANTIVIRALS | PHARMACIA & UPJOHN COMPANY (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040138449-A1 | Antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-07-15 | — | — | US | disclosed |
| US-20030207877-A1 | Pyridoquinoxaline antivirals | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
| WO-2003059912-A1 | OXOTHIENO (3, 2-B) PYRIDINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003059878-A2 | THIENO (3, 2-B) PYRIDONES AS ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003059911-A2 | 4-OXO-4, 7-DIHYDROFURO[2,3-b]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003053971-A1 | PYRIDOQUINOXALINE ANTIVIRALS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207877-A1 | Pyridoquinoxaline antivirals | IFNAR1, SARS1, ZC3HAV1 | KDM4E 1145/4885HIF1A 3740/4885TDP1 1002/4885 |
| US-20040259907-A1 | 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | IL4, ZC3HAV1, IRF3 | KDM4E 42/4885HIF1A 1232/4885TDP1 1612/4885 |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, IRF3, IFNAR1 | KDM4E 1156/4885HIF1A 1264/4885TDP1 704/4885 |
| US-20040138449-A1 | Antiviral agents | IRF3, IFNAR1, EIF2AK2 | KDM4E 1593/4885HIF1A 1529/4885TDP1 396/4885 |
| US-20050049245-A1 | Heteroaryl-ethanolamine derivatives as antiviral agents | RPL35, ZC3HAV1, RPL5 | KDM4E 775/4885HIF1A 2960/4885TDP1 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.